Taubman Institute hosts webinar on transplantation immunology
Join Michigan Medicine’s Daniel Goldstein, M.D., and renowned human transplantation immunology researchers on Monday, Oct. 12 from 9 a.m. until noon for an update on their Taubman Institute Innovation Project (TIIP) that aims to refine the use of immune-suppression drugs in solid organ transplant patients.
Goldstein heads a team of three Michigan Medicine primary investigators in this TIIP, Development of a novel precision medicine approach in solid organ transplantation – or “ImPrec” for short.
Vibha Lama, M.D., and Fei Wen, Ph.D., are co-PIs.
Drugs that suppress the immune system to keep the body from rejecting donated organs also lower the patient’s ability to fight off infections – and immune suppression can increase the risk of certain cancers.
Doctors aim for dosages that are high enough to prevent rejection, yet not so high that the patient is vulnerable to infections and cancer – but they have few tools for measuring these relative risks.
Developing a method to predict a patient’s risk of immunity-related side effects — instead of reacting after problems arise – is the goal of ImPrec. As the project approaches its first anniversary, Goldstein has asked the three experts to assist him and his team in a review the work they have done within the past year.
Registration is required attend this free, informative Zoom webinar. All are welcome.